The reporter learned that after irradiation by the China Mianyang Research Reactor (CMRR) of the Institute of Nuclear Physics and Chemistry of the China Academy of Engineering Physics, the gram level ytterbium-176 isotope produced by the Nuclear Industry Physics and Chemical Engineering Research Institute/Co., Ltd. of China National Nuclear Corporation (hereinafter referred to as the "Institute/Company") successfully prepared a carrier free lutetium-177 radioactive isotope product of 1.59Ci (Curie, radioactive intensity unit), and all indicators were qualified, The radioactive nuclear purity is greater than 99.9%, achieving a new breakthrough in the domestic nuclear drug industry chain. Lutetium-177 is an ideal radioactive medical isotope that releases β The particles can be used for new radioimmunotherapy of prostate cancer, breast cancer and other diseases; Radiating γ X-rays are suitable for diagnostic imaging and evaluation of radiation therapy effects, and have broad application prospects in clinical practice. Ytterium-176 is the main raw material for producing luteti-177, which previously relied on imports for a long time. The successful preparation of luteti-177 marks the adoption of advanced technology by the research and development team of the Institute of Nuclear Physics and Chemistry/company to produce ytterbium 176 isotopes that meet the technical indicators of nuclear drug production, achieving independent and controllable supply of ytterbium 176 isotope materials in China, and providing important guarantees for breaking the monopoly of key nuclear drug materials and entering the international market. Based on this achievement, the Nuclear Institute/Company is actively integrating resources and deploying engineering applications. It is expected to form an annual production capacity of Yb-176 isotopes in the order of hundreds of grams by 2025, injecting strong technological power into the cultivation and development of new productive forces for China's medical isotope industry. (Lai Xin She)